Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cook

Showing results (781-790 of 793) with videos related to

Pageof 80
Sort By:
JCO Precision Oncology|September 27, 2021
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis PredictionEric D Whitman, Vadim P Koshenkov, Brian R Gastman, et al.
Journal of Medicinal Chemistry|September 21, 2011
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.
Genes|January 21, 2023
Evolutionary Landscape of <i>SOX</i> Genes to Inform Genotype-to-Phenotype RelationshipsAdam Underwood, Daniel T Rasicci, David Hinds, et al.
MMWR. Morbidity and Mortality Weekly Report|June 15, 2023
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023Kevin C Ma, Philip Shirk, Anastasia S Lambrou, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
American Journal of Physiology. Cell Physiology|July 25, 2025
Methyl-CpG-binding domain as a protein interaction partner in promoter regulation and neurodevelopment through evolutionary expanded entanglementStephanie M Bilinovich, Surya B Chhetri, Jackson T Mitchell, et al.
ACS Medicinal Chemistry Letters|February 19, 2025
Design of Potent Menin-KMT2A Interaction Inhibitors with Improved <i>In Vitro</i> ADME Properties and Reduced hERG AffinityBruno D Chapsal, Jennifer R Kimbrough, Stephanie M Bester, et al.
Medrxiv : the Preprint Server for Health Sciences|February 17, 2021
Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United StatesTara Alpert, Anderson F Brito, Erica Lasek-Nesselquist, et al.
Cell|April 23, 2021
Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United StatesTara Alpert, Anderson F Brito, Erica Lasek-Nesselquist, et al.
MMWR. Morbidity and Mortality Weekly Report|February 10, 2022
Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants - United States, June 2021-January 2022Anastasia S Lambrou, Philip Shirk, Molly K Steele, et al.
Pageof 80

Showing results (781-790 of 793) with videos related to

Sort By:
Pageof 80
JCO Precision Oncology|September 27, 2021
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis PredictionEric D Whitman, Vadim P Koshenkov, Brian R Gastman, et al.
Journal of Medicinal Chemistry|September 21, 2011
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)Travis T Wager, Betty A Pettersen, Anne W Schmidt, et al.
Genes|January 21, 2023
Evolutionary Landscape of <i>SOX</i> Genes to Inform Genotype-to-Phenotype RelationshipsAdam Underwood, Daniel T Rasicci, David Hinds, et al.
MMWR. Morbidity and Mortality Weekly Report|June 15, 2023
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023Kevin C Ma, Philip Shirk, Anastasia S Lambrou, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
American Journal of Physiology. Cell Physiology|July 25, 2025
Methyl-CpG-binding domain as a protein interaction partner in promoter regulation and neurodevelopment through evolutionary expanded entanglementStephanie M Bilinovich, Surya B Chhetri, Jackson T Mitchell, et al.
ACS Medicinal Chemistry Letters|February 19, 2025
Design of Potent Menin-KMT2A Interaction Inhibitors with Improved <i>In Vitro</i> ADME Properties and Reduced hERG AffinityBruno D Chapsal, Jennifer R Kimbrough, Stephanie M Bester, et al.
Medrxiv : the Preprint Server for Health Sciences|February 17, 2021
Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United StatesTara Alpert, Anderson F Brito, Erica Lasek-Nesselquist, et al.
Cell|April 23, 2021
Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United StatesTara Alpert, Anderson F Brito, Erica Lasek-Nesselquist, et al.
MMWR. Morbidity and Mortality Weekly Report|February 10, 2022
Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants - United States, June 2021-January 2022Anastasia S Lambrou, Philip Shirk, Molly K Steele, et al.
Pageof 80